Markets

TuHURA Biosciences Secures US Patent For TBS-2025, Entitled ‘Anti-VISTA Antibodies And Uses Thereof’

Oct 13, 2026 · 07:48 AM ET· updated 1h ago

Patent extends coverage to include bispecific/multi-specific antibodies across all classes of human antibodiesTAMPA, Fla., Oct. 13, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the

Why It Matters

TuHURA won a patent for a new type of medicine called TBS-2025. This gives the company legal protection to sell this medicine and similar ones.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

HURA1.93

-0.03 (-1.53%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.